(NASDAQ: BBIO) Bridgebio Pharma's forecast annual revenue growth rate of 69.27% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.72%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.02%.
Bridgebio Pharma's revenue in 2026 is $502,076,000.On average, 25 Wall Street analysts forecast BBIO's revenue for 2026 to be $185,044,048,998, with the lowest BBIO revenue forecast at $149,479,905,313, and the highest BBIO revenue forecast at $252,215,595,171. On average, 24 Wall Street analysts forecast BBIO's revenue for 2027 to be $321,812,365,860, with the lowest BBIO revenue forecast at $209,565,763,551, and the highest BBIO revenue forecast at $463,526,124,561.
In 2028, BBIO is forecast to generate $475,157,896,821 in revenue, with the lowest revenue forecast at $355,544,505,414 and the highest revenue forecast at $583,333,378,839.